BridgeBio Pharma (BBIO) Insider Valantine Sells 2,808 Shares

Hannah Valantine, an insider at BridgeBio Pharma, Inc. (NasdaqGS: BBIO), sold 2,808 shares of the company on June 22, 2026. This transaction is part of recent insider activity reported for the biotechnology firm.

Insider Buying and Selling at BridgeBio Pharma, Inc.

In addition to Valantine's sale, other notable insider transactions include Jennifer Cook's planned sale of 21,967 shares at $70 on June 24, 2026, and Eric Aguiar's purchase of 3,990 shares on June 22, 2026. These transactions highlight ongoing insider activity within the company.

BridgeBio Pharma, Inc. Stock Up 2.2%

Shares of BridgeBio Pharma traded near $68.63 on Thursday. The company has a market cap of approximately $13.5 billion and a forward P/E ratio of 130.7, reflecting its valuation based on expected future earnings. The stock's 52-week range is between $41.30 and $84.94, and it has a beta of 0.975, indicating moderate volatility. The company's 50-day moving average is $69.67, and the 200-day moving average is $67.55.

Other Institutional Activity in BridgeBio Pharma

Institutional investors have also been active in BridgeBio Pharma. BlackRock, Inc. reduced its holdings by 341,772 shares, ending with 14,207,757 shares valued at about $1.05 billion, representing a 2.3% decrease. Meanwhile, Janus Henderson Group PLC increased its position by 2,178,556 shares, totaling 13,179,013 shares worth approximately $978.6 million, marking a 19.8% increase. Viking Global Investors LP cut its stake by 2,551,500 shares to 11,842,434 shares, a 17.7% decrease. Farallon Capital Management LLC added 367,000 shares, bringing its total to 9,365,463 shares valued around $695.5 million, a 4.1% increase. Vanguard Portfolio Management LLC opened a new position with 8,080,573 shares valued at $600.1 million.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for BridgeBio Pharma. On June 16, 2026, Mizuho maintained its buy rating with a $96 price target. Earlier, on June 3, Canaccord Genuity initiated coverage with a buy rating and a $104 target. Citigroup initiated a hold rating with an $82 target on May 19. Overall, the stock has a consensus strong buy recommendation with a mean price target of $102.28.

About BridgeBio Pharma

BridgeBio Pharma, Inc. is a biopharmaceutical company based in Palo Alto, California. It focuses on discovering, developing, and delivering medicines for patients with genetic diseases. Its portfolio includes treatments for cardiomyopathy, molybdenum cofactor deficiency, and achondroplasia, among others. The company was founded in 2015 and is led by CEO Dr. Neil Kumar.

Bottom Line

Hannah Valantine's recent sale of BridgeBio Pharma shares is part of ongoing insider activity at the company. Investors keep a close watch on such transactions as they can provide insights into insider sentiment. BridgeBio's stock performance and institutional activity are also key areas of interest, especially given the company's focus on genetic disease treatments and its current market valuation.